Tendon Repair Stack

This stack's effectiveness lies in targeting tendon repair through three distinct but complementary mechanisms, creating a comprehensive healing environment.

BPC-157 serves as the foundation, promoting angiogenesis (new blood vessel formation) and modulating the inflammatory response. Research demonstrates its ability to upregulate growth factors like VEGF whilst accelerating the transition from inflammatory to proliferative healing phases. This peptide also appears to enhance tendon-to-bone healing—particularly valuable for insertion point injuries.

TB-500 contributes through its unique actin-binding properties, promoting cellular migration and tissue remodelling. Studies indicate it enhances keratinocyte and endothelial cell migration, whilst reducing inflammatory markers. Its ability to promote stem cell differentiation makes it particularly valuable during the proliferative phase of tendon healing, when new tissue architecture is being established.

IGF-1 LR3 provides the growth stimulus needed for robust tissue regeneration. This extended half-life variant of IGF-1 promotes satellite cell activation and enhances collagen synthesis—both critical for developing strong, functional tendon tissue. Research suggests IGF-1's role in promoting tenocyte proliferation and improving the mechanical properties of healing tendons.

Together, these peptides address the entire healing cascade: BPC-157 optimises the inflammatory environment, TB-500 enhances cellular movement and remodelling, and IGF-1 LR3 drives the growth processes needed for strong, lasting repair. This multi-target approach explains why users report more complete recovery compared to single-peptide protocols.

BPC-157: 250-500mcg daily, administered subcutaneously as close to the injury site as practical. For elbow tendinitis, inject into the lateral forearm; for Achilles issues, target the posterior lower leg. Split into two 125-250mcg doses if using higher amounts, spacing 12 hours apart. Continue for 4-6 weeks.

TB-500: Loading phase of 2mg twice weekly for first 4 weeks, followed by 2mg weekly for maintenance. Inject subcutaneously, rotating injection sites around the torso. TB-500 is systemic, so precise location matters less than with BPC-157. Many users inject abdomen or thigh for convenience.

IGF-1 LR3: 50-100mcg daily, 5 days on, 2 days off to prevent receptor downregulation. Inject subcutaneously post-workout when possible, as exercise enhances IGF-1 receptor sensitivity. Limit cycles to 4-6 weeks maximum due to potency.

Timing Strategy: Administer BPC-157 morning and evening, TB-500 on Monday/Thursday (loading) or just Monday (maintenance), and IGF-1 LR3 post-workout or before bed. Space injections by at least 30 minutes when combining multiple peptides.

Reconstitution: All peptides require bacteriostatic water. Store reconstituted vials refrigerated for up to 28 days. Use our reconstitution calculator to determine precise mixing ratios for your vial sizes.

Injection Sites: Rotate sites to prevent tissue irritation. Use insulin syringes (29-31 gauge) for comfort. Clean injection sites with alcohol and allow peptides to reach room temperature before injecting.

Week 1-2: Initial anti-inflammatory effects become apparent. Many users report reduced morning stiffness and improved pain levels during rest. Sleep quality often improves as inflammatory markers decrease.

Week 3-4: Functional improvements emerge as tissue repair accelerates. Range of motion typically increases, and users report reduced pain during light activities. This phase marks the transition from inflammatory to proliferative healing.

Month 2: Significant strength gains become evident. Users can typically resume modified training protocols. Tissue quality improvements are noticeable, with less morning stiffness and improved response to loading.

Month 3 and Beyond: Full functional restoration for many users, though severe or chronic injuries may require longer protocols. Tendon strength approaches pre-injury levels. Many report improved resilience to future injury, suggesting enhanced tissue quality rather than just symptom masking.

Note: Individual responses vary considerably. Acute injuries typically respond faster than chronic conditions. Combining this protocol with appropriate physiotherapy and progressive loading enhances outcomes significantly.

This stack is generally well-tolerated, though several considerations apply. BPC-157 rarely produces side effects, though some users report mild fatigue or dizziness initially—likely related to improved healing processes rather than direct peptide effects.

TB-500 may cause mild lethargy or head pressure in sensitive individuals. These effects typically resolve within the first week. Some users report increased appetite or slight water retention.

IGF-1 LR3 carries the highest risk profile. Potential hypoglycaemia requires careful monitoring, particularly when combined with exercise. Users with diabetes should consult healthcare providers. Excessive dosing may cause joint pain or carpal tunnel symptoms.

Contraindications: Avoid if pregnant, breastfeeding, or with active malignancies due to growth-promoting properties. Those with insulin resistance should monitor glucose levels carefully. History of cancer warrants particular caution with IGF-1 LR3.

UK Legal Status: These peptides exist in a regulatory grey area. Review our UK peptide legality guide for current status. Purchase only from reputable suppliers offering third-party testing certificates.

Always start with minimum effective doses and assess tolerance before increasing. Consider working with knowledgeable healthcare providers familiar with peptide protocols.